A COMPREHENSIVE REVIEW OF INFLIXIMAB AS A TARGETED THERAPEUTIC CHOICE IN INFLAMMATORY DISORDERS
Rajamanickam Palaniyappan*, Saravanakumar Arthanari, Mohanraj Subramanian, Ragupathi Ganesan, Anandharaj Govindaraj, Mukesh Kumar, Pragadeesh Kandhasamy, Mahadurai Gopal, Janani Thangarasu, Induja Manikantan and Sweatha Dhandapani
ABSTRACT
Infliximab is a potent monoclonal antibody that has revolutionized the treatment of various inflammatory and autoimmune diseases. This captivating abstract takes you on a captivating journey through the world of infliximab, unraveling its mechanism of action, adverse effect, contraindication, outstanding efficacy. The drug infliximab was developed by Jan vilcek at New York university school of medicine and by the centocor company. Firstly, the drug infliximab approved by United States of America for the treatment of fistulizing disease and Crohn's disease. The drug infliximab first known as cA2, which is now marketed as Remicade. At the core of infliximab's triumph lies its remarkable ability to target tumor necrosis factor-alpha (TNF-α). Infliximab efficiently inhibits the inflammatory signaling system by preferentially binding to tumor necrosis factor-alpha (TNF-α), resulting in significant decreases in disease activity. Approximately 100% when administered intravenously due to its direct entry into the systemic circulation. This high bioavailability contributes to its consistent and predictable therapeutic effects. Many clinical studies demonstrated infliximab's excellent effectiveness. Infliximab is not manufactured chemically. It is a monoclonal antibody produced using recombinant DNA technology. While infliximab presents multiple benefits it is critical to be aware of any potential side effects. Among the recognized dangers of infliximab medication include infusion reactions, increased susceptibility to infections, and Malignancy and then it is contraindicated with heart failure, severe hypersensitivity reaction.
Keywords: Remicade, monoclonal antibody, tumor necrosis factor-alpha, immunosuppressive agent.
[Full Text Article]
[Download Certificate]
Impact Factor : 8.181 
